News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanobiotix Presents Successful Phase I Results For Its Lead Nanomedicine Product NBTXR3 At American Society of Clinical Oncology



6/2/2014 9:57:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS, June 2, 2014 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented today at the American Society of Clinical Oncology (ASCO) annual meeting

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   
Sarcoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES